Gates Foundation Strategic Investment Fund Logo
Share this page:

Business Wire: Lyndra Therapeutics Raises $55 Million in Series B Financing

January 29, 2019

WATERTOWN, Mass.–(BUSINESS WIRE)– Lyndra Therapeutics, which is moving toward making daily pills a thing of the past, today announced it has raised $55 million in Series B financing, funds it will use for Phase II clinical trials, expansion of its Phase I pipeline and manufacturing scale-up. All original investors from the company’s $23 million Series A round, led by Polaris Partners, resubscribed, and new investors include HOPU Investments, Gilead Sciences, Invus, the Bill & Melinda Gates Foundation and Orient Life.

Read the full text here.